Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Monday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock.

Separately, Oppenheimer upped their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Trading Up 5.7 %

Shares of ATXS opened at $7.79 on Monday. The business’s 50-day moving average price is $9.68 and its 200 day moving average price is $10.67. The stock has a market capitalization of $439.62 million, a P/E ratio of -3.73 and a beta of 0.70. Astria Therapeutics has a 1-year low of $6.94 and a 1-year high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Large investors have recently made changes to their positions in the business. Quest Partners LLC grew its position in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $140,000. SG Americas Securities LLC acquired a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $155,000. Hsbc Holdings PLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter valued at $171,000. Finally, Intech Investment Management LLC acquired a new position in shares of Astria Therapeutics in the third quarter worth $228,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.